Difference between revisions of "Global Template"
Jump to navigation
Jump to search
| [unchecked revision] | [unchecked revision] |
| Line 73: | Line 73: | ||
===Additional Description:=== | ===Additional Description:=== | ||
| − | Other Mutations | + | *Other Mutations |
| − | Concomitant Mutations | + | *Concomitant Mutations |
| − | Secondary Mutations | + | *Secondary Mutations |
| − | Mutually Exclusive | + | *Mutually Exclusive |
| − | |||
==Epigenomics (Methylation)== | ==Epigenomics (Methylation)== | ||
Revision as of 13:17, 9 April 2017
Global Template
Primary Author(s)
Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome.
Cancer Category/Type
Cancer Sub-Classification / Subtype
Definition / Description of Disease
Synonyms / Terminology
Epidemiology / Prevalence
Clinical Features
Sites of Involvement
Morphologic Features
Immunophenotype
| Finding | Marker |
|---|---|
| Positive (universal) | CD1 |
| Positive (subset) | CD2 |
| Negative (universal) | CD3 |
| Negative (subset) | CD4 |
Additional Description:
Chromosomal Rearrangements (Gene Fusions)
| Chromosomal Rearrangement | Genes in Fusion (5’ or 3’ Segments) | Pathogenic Derivative | Prevalence |
|---|---|---|---|
| t(9;22) | BCR-ABL1 | der(22) | 5% |
| t(8;21) | RUNX1-RUNXT1 | der(8) | 5% |
Additional Description:
Characteristic Chromosomal Aberrations / Patterns
Genomic Gain/Loss/LOH
Chromosome Number Gain/Loss/Amp/LOH Region
Additional Description:
Gene Mutations (SNV/INDEL)
Gene Mutation Oncogene/Tumor Suppressor/Other Presumed Mechanism (LOF/GOF/Other; Driver/Passenger) Prevalence (COSMIC/TCGA/Other)
Additional Description:
- Other Mutations
- Concomitant Mutations
- Secondary Mutations
- Mutually Exclusive
Epigenomics (Methylation)
Genes and Main Pathways Involved
Diagnostic Testing Methods
Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications)
Familial Forms
Other Information
Links
References
Reference Example, BOOK
- Arber DA, Brunning RD, Le Beau MM, Falini B, Vardiman JW, Porwit A, Thiele J, Bloomfield CD (2008). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4thedition.Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, Editors. IARC Press: Lyon, France, p117-118.
Reference Example, Journal Article
- Li Y, Mehta PK, Nizetic D, Kaneko Y, Chan GCF, Chan LC, Squire J, Scherer SW and Hitzler JK (2001). Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. Nat Genet 28:220-221, PMID 11431691.